acr vs mbp

great play for the coming weeks

Outlook 2007:

Evamist (1,5 B$ Market) FDA approval in Juli 2007
Testosterone MD-Lotion Phase 2 results in Juli
Testosterone MDTS start Phase 3 Mid-2007

http://www.acrux.com.au/IRM/Company/ShowPage.aspx?CPID=1193

In our view, these elements, combined with ACR’s extensive pipeline of
product, provide one of the best investment opportunities in the sector. We
expect our price target of $1.90 will be achieved within the next 12-months
and could easily be exceeded if ACR continues to stand and deliver good
commercial outcomes.